Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies for patients with advanced cancers. This news hub provides investors and healthcare professionals with timely updates on the company’s clinical developments, regulatory milestones, and strategic partnerships.
Access authoritative information about Actinium’s Antibody Radiation Conjugate (ARC) platform, including progress on lead candidates Iomab-B for bone marrow transplant conditioning and Iomab-ACT for CAR-T therapy preparation. Our curated news collection features press releases on trial results, FDA communications, and collaborations with leading cancer research centers.
Key updates include phase 3 trial data for hematologic malignancies, manufacturing advancements for radiotherapy agents, and scientific presentations at major oncology conferences. All content is vetted for accuracy and relevance to treatment innovation in cellular therapies.
Bookmark this page for streamlined tracking of Actinium’s progress in redefining cancer treatment paradigms through precision radiotherapy. Verify time-sensitive updates directly through SEC filings and official company communications.
Aon (NYSE: AON) reported third-quarter 2025 results for the three months ended September 30, 2025, with $3.997B total revenue, up 7% year-over-year and 7% organic revenue growth. Operating income rose to $816M (+31%) and operating margin improved to 20.4% (up 370 bps). Diluted EPS was $2.11 (+34%) and adjusted EPS was $3.05 (+12%). Cash provided by operations was $1.148B (+13%) and free cash flow was $1.079B (+13%) for the quarter. Risk Capital revenue was $2.5B (+7%) and Human Capital revenue was $1.5B (+8%). The company repurchased ~0.7M shares for ~$250M and has ~$1.6B remaining repurchase authorization.
Management reiterated confidence in achieving full-year 2025 guidance and emphasized execution of its Aon United 3x3 Plan and continued investments via Aon Business Services.
Philip Morris International (NYSE:PM) announced on October 28, 2025 that its U.S. businesses (PMI U.S.) were certified as a Great Place to Work and recognized as a USA TODAY Top Workplace, including honors for Top Woman-Led Company and excellence in professional development, employee appreciation, and well-being.
The recognition is based on direct employee feedback and workplace evaluations and builds on other national honors, including being named one of America's Best Companies 2025 by Forbes and being highlighted by U.S. News & World Report for project management leadership tied to the 2025 Pulse of the Profession report. PMI U.S. employs more than 3,000 people in the U.S. and operates manufacturing sites in Owensboro, Kentucky, and Wilson, North Carolina.
Actinium Pharmaceuticals (NYSE: ATNM) presented preclinical data on ATNM-400, a first-in-class Ac-225 antibody radioconjugate targeting a non-PSMA antigen, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat on Oct 24, 2025. ATNM-400 showed superior tumor control and prolonged survival versus enzalutamide, 177Lu-PSMA-617 and 225Ac-PSMA-617 in 22Rv1 and other models, including ~5× longer tumor control and ~2× longer overall survival versus 177Lu-PSMA-617. Combination with enzalutamide produced complete regressions in 40% of animals. Data support PSMA-independent activity and potential use as monotherapy, combination, or sequential therapy.
Actinium Pharmaceuticals (NYSE: ATNM) announced that first-ever preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, will be presented at the AACR-NCI-EORTC conference Oct 22–26, 2025.
Preclinical findings reportedly show potent anti-tumor activity in EGFR-mutant NSCLC models, overcoming resistance to osimertinib and showing synergy with osimertinib and with enzalutamide in prostate models; animal data included 40% complete tumor regressions in a prostate setting. The poster is scheduled for Oct 25, 2025, and the abstract will be available online Oct 22, 2025 at 12:00 PM ET.
Actinium (NYSE: ATNM) announced that preclinical data for ATNM-400, a first-in-class Ac-225 antibody radioconjugate, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat on October 23, 2025. The poster highlights durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including activity in tumors resistant to enzalutamide and 177Lu-PSMA-617, and reports superior efficacy versus 225Ac-PSMA-617.
The release states ATNM-400 targets a distinct, non-PSMA antigen that is overexpressed after ARPI therapy, showed synergy with enzalutamide, and improved overall survival in preclinical models. The poster will be viewable online via the company investor relations page after the retreat.
Adient (NYSE) and Autoliv announced a co-developed safety solution for deeply reclined (zero-gravity) seating now ready for mass production. The system pairs Adient’s Z-Guard seating concept with Autoliv safety technologies to protect head, neck, chest and pelvis in reclined positions.
Key elements include an active cushion collapse mechanism, an adjustable seat belt outlet, integrated seatbelt system, dynamic lumbar retractor, pelvic cushion airbag and head side airbag. Z-Guard also supports predictive, high-speed seat repositioning via vehicle driver assistance integration and is scheduled for production in a high-volume model from a major global OEM.
Alexander & Baldwin (NYSE: ALEX) will report third quarter 2025 results after market close on Thursday, October 30, 2025. A conference call and webcast to discuss operating and financial performance is scheduled the same day at 5:00 p.m. ET.
Company participants include Lance Parker (president and CEO) and Clayton Chun (EVP, CFO and treasurer) with other senior management. Sell-side analysts may ask questions during the live call; webcast listeners will be in listen-only mode. Dial-in and webcast links and earnings documents will be available after market close on October 30, 2025.
Uber (NYSE:UBER) and Baidu (NASDAQ:BIDU) have announced a strategic multi-year partnership to deploy thousands of Baidu's Apollo Go autonomous vehicles on Uber's platform across global markets, excluding the US and mainland China.
The partnership will launch first in Asia and the Middle East in 2025, where riders requesting qualifying Uber trips may have their rides fulfilled by fully driverless Apollo Go vehicles. Apollo Go currently operates over 1,000 fully driverless vehicles across 15 cities, including Dubai and Abu Dhabi, and has completed more than 11 million cumulative rides.
Actinium Pharmaceuticals (NYSE: ATNM) has presented promising preclinical results for ATNM-400, a novel targeted radiotherapy for prostate cancer, at the AACR Annual Meeting. The data shows ATNM-400 outperforms Pluvicto, achieving 99.8% tumor growth inhibition with a single 40 µCi/kg dose.
Unlike Pluvicto and most prostate cancer radiotherapies that target PSMA, ATNM-400 is a first-in-class treatment targeting a distinct non-PSMA receptor that remains highly expressed even after Pluvicto treatment. The therapy utilizes Actinium-225, a more potent alpha-particle emitter than Lutetitium-177, causing irreversible DNA breaks with potentially fewer off-target effects.
Key findings demonstrate ATNM-400's efficacy in Pluvicto-resistant tumors, rapid internalization, sustained tumor uptake, and efficient clearance from essential organs. The treatment was well-tolerated with no apparent toxicities at both tested dose levels.
